MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 530935 | Name: nor-NOHA acetate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

nor-NOHA is a potent, selective, competitive, and high affinity inhibitor of arginase. nor-NOHA inhibits arginase from rat liver (IC50 = 2 µM) and mouse macrophages (IC50 = 50 µM).

Chemical Structure

nor-NOHA acetate
nor-NOHA acetate
CAS#1140844-63-8 (acetate)

Theoretical Analysis

MedKoo Cat#: 530935

Name: nor-NOHA acetate

CAS#: 1140844-63-8 (acetate)

Chemical Formula: C9H20N4O7

Exact Mass: 0.0000

Molecular Weight: 296.28

Elemental Analysis: C, 36.49; H, 6.80; N, 18.91; O, 37.80

Price and Availability

Size Price Availability Quantity
5mg USD 250.00 2 Weeks
10mg USD 450.00 2 Weeks
50mg USD 1,150.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
189302-40-7 (free base) 1140844-63-8 (acetate) 291758-32-2 (HCl) 2250019-93-1 (mono acetate)
Synonym
nor-NOHA acetate, N(ω)-hydroxy-nor-L-arginine.
IUPAC/Chemical Name
(2S)-2-Amino-(4-(2ʹ-hydroxyguanidino))butyric Acid; acetic acid (1:2)
InChi Key
PQFYTZJPYBMTCT-QTNFYWBSSA-N
InChi Code
InChI=1S/C5H12N4O3.2C2H4O2/c6-3(4(10)11)1-2-8-5(7)9-12;2*1-2(3)4/h3,12H,1-2,6H2,(H,10,11)(H3,7,8,9);2*1H3,(H,3,4)/t3-;;/m0../s1
SMILES Code
O=C(O)[C@@H](N)CCN/C(N)=N/O.CC(O)=O.CC(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
nor-NOHA acetate (Nω-Hydroxy-nor-L-arginine acetate) is a specific and reversible arginase inhibitor.
In vitro activity:
This study therefore explored if the clinically-tested arginase inhibitor Nω-hydroxy-nor-arginine (nor-NOHA) would be effective against leukemic cells under hypoxic conditions. Remarkably, nor-NOHA effectively induced apoptosis in ARG2-expressing cells under hypoxia but not normoxia. Co-treatment with nor-NOHA overcame hypoxia-mediated resistance towards BCR-ABL1 kinase inhibitors. Reference: PLoS One. 2018 Oct 11;13(10):e0205254. https://pubmed.ncbi.nlm.nih.gov/30307989/
In vivo activity:
AIA (adjuvant-induced arthritis) rats were treated with nor-NOHA (40 mg/kg/d, ip) for 21 days after the onset of arthritis. Nor-NOHA treatment fully restored the aortic response to Ach to that of healthy controls. The results showed that this beneficial effect is mediated by an increase in NOS activity and EDHF and reduced superoxide anion production as well as a decrease in the activity of cyclooxygenase (COX)-2, thromboxane and prostacyclins synthases. In addition, nor-NOHA decreased IL-6 and VEGF plasma levels in AIA rats. By contrast, the treatment did not modify arthritis severity in AIA rats. Reference: Arthritis Res Ther. 2012 May 30;14(3):R130. https://pubmed.ncbi.nlm.nih.gov/22647483/
Solvent mg/mL mM
Solubility
DMF 1.0 3.38
DMSO 27.5 92.82
Ethanol 50.0 168.76
PBS (pH 7.2) 10.0 33.75
Water 114.5 386.46
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 296.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Ng KP, Manjeri A, Lee LM, Chan ZE, Tan CY, Tan QD, Majeed A, Lee KL, Chuah C, Suda T, Ong ST. The arginase inhibitor Nω-hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target. PLoS One. 2018 Oct 11;13(10):e0205254. doi: 10.1371/journal.pone.0205254. PMID: 30307989; PMCID: PMC6181325. 2. Tenu JP, Lepoivre M, Moali C, Brollo M, Mansuy D, Boucher JL. Effects of the new arginase inhibitor N(omega)-hydroxy-nor-L-arginine on NO synthase activity in murine macrophages. Nitric Oxide. 1999 Dec;3(6):427-38. doi: 10.1006/niox.1999.0255. PMID: 10637120. 3. Prati C, Berthelot A, Kantelip B, Wendling D, Demougeot C. Treatment with the arginase inhibitor Nw-hydroxy-nor-L-arginine restores endothelial function in rat adjuvant-induced arthritis. Arthritis Res Ther. 2012 May 30;14(3):R130. doi: 10.1186/ar3860. PMID: 22647483; PMCID: PMC3446511.
In vitro protocol:
1. Ng KP, Manjeri A, Lee LM, Chan ZE, Tan CY, Tan QD, Majeed A, Lee KL, Chuah C, Suda T, Ong ST. The arginase inhibitor Nω-hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target. PLoS One. 2018 Oct 11;13(10):e0205254. doi: 10.1371/journal.pone.0205254. PMID: 30307989; PMCID: PMC6181325. 2. Tenu JP, Lepoivre M, Moali C, Brollo M, Mansuy D, Boucher JL. Effects of the new arginase inhibitor N(omega)-hydroxy-nor-L-arginine on NO synthase activity in murine macrophages. Nitric Oxide. 1999 Dec;3(6):427-38. doi: 10.1006/niox.1999.0255. PMID: 10637120.
In vivo protocol:
1. Prati C, Berthelot A, Kantelip B, Wendling D, Demougeot C. Treatment with the arginase inhibitor Nw-hydroxy-nor-L-arginine restores endothelial function in rat adjuvant-induced arthritis. Arthritis Res Ther. 2012 May 30;14(3):R130. doi: 10.1186/ar3860. PMID: 22647483; PMCID: PMC3446511.
1: Havlínová Z, Hroch M, Nagy A, Sišpera L, Holeček M, Chládek J. Single- and multiple-dose pharmacokinetics of arginase inhibitor Nω-hydroxy-nor-L-arginine, and its effect on plasma amino acids concentrations in Wistar rats. Gen Physiol Biophys. 2014;33(2):189-98. doi: 10.4149/gpb_2013078. Epub 2013 Oct 31. PubMed PMID: 24177023. 2: Hu H, Moon J, Chung JH, Kim OY, Yu R, Shin MJ. Arginase inhibition ameliorates adipose tissue inflammation in mice with diet-induced obesity. Biochem Biophys Res Commun. 2015 Aug 28;464(3):840-7. doi: 10.1016/j.bbrc.2015.07.048. Epub 2015 Jul 16. PubMed PMID: 26188090. 3: Rodríguez-Gómez I, Manuel Moreno J, Jimenez R, Quesada A, Montoro-Molina S, Vargas-Tendero P, Wangensteen R, Vargas F. Effects of Arginase Inhibition in Hypertensive Hyperthyroid Rats. Am J Hypertens. 2015 Dec;28(12):1464-72. doi: 10.1093/ajh/hpv049. Epub 2015 Apr 23. PubMed PMID: 25907224. 4: Havlinova Z, Babicova A, Hroch M, Chladek J. Comparative pharmacokinetics of N(ω)-hydroxy-nor-L-arginine, an arginase inhibitor, after single-dose intravenous, intraperitoneal and intratracheal administration to brown Norway rats. Xenobiotica. 2013 Oct;43(10):886-94. doi: 10.3109/00498254.2013.780672. Epub 2013 Mar 21. PubMed PMID: 23517541. 5: Risse PA, Lavoie-Lamoureux A, Jo T, Tsuchiya K, Siddiqui S, Martin JG. Airway arginase expression and Nω-hydroxy-nor-arginine effect on methacholine-induced bronchoconstriction differentiate Lewis and Fischer rat strains. J Appl Physiol (1985). 2014 Mar 15;116(6):621-7. doi: 10.1152/japplphysiol.01241.2013. Epub 2014 Feb 6. PubMed PMID: 24505101. 6: Reid KM, Tsung A, Kaizu T, Jeyabalan G, Ikeda A, Shao L, Wu G, Murase N, Geller DA. Liver I/R injury is improved by the arginase inhibitor, N(omega)-hydroxy-nor-L-arginine (nor-NOHA). Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G512-7. Epub 2006 Oct 5. PubMed PMID: 17023552. 7: Li H, Meininger CJ, Bazer FW, Wu G. Intracellular sources of ornithine for polyamine synthesis in endothelial cells. Amino Acids. 2016 Oct;48(10):2401-10. doi: 10.1007/s00726-016-2256-6. Epub 2016 May 14. PubMed PMID: 27180260. 8: Prati C, Berthelot A, Kantelip B, Wendling D, Demougeot C. Treatment with the arginase inhibitor Nw-hydroxy-nor-L-arginine restores endothelial function in rat adjuvant-induced arthritis. Arthritis Res Ther. 2012 May 30;14(3):R130. doi: 10.1186/ar3860. PubMed PMID: 22647483; PubMed Central PMCID: PMC3446511. 9: Bagnost T, Guillaume YC, Thomassin M, Robert JF, Berthelot A, Xicluna A, André C. Immobilization of arginase and its application in an enzymatic chromatographic column: thermodynamic studies of nor-NOHA/arginase binding and role of the reactive histidine residue. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 1;856(1-2):113-20. Epub 2007 Jun 2. PubMed PMID: 17588506. 10: Lasch M, Caballero-Martinez A, Troidl K, Schloegl I, Lautz T, Deindl E. Arginase inhibition attenuates arteriogenesis and interferes with M2 macrophage accumulation. Lab Invest. 2016 Aug;96(8):830-8. doi: 10.1038/labinvest.2016.62. Epub 2016 May 30. PubMed PMID: 27239731. 11: Bagnost T, Guillaume YC, Thomassin M, Berthelot A, Demougeot C, André C. Biochromatographic framework for analyzing magnesium chloride salt dependence on nor-NOHA binding to arginase enzyme. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Sep 15;873(1):37-40. doi: 10.1016/j.jchromb.2008.07.024. Epub 2008 Jul 29. PubMed PMID: 18723409. 12: Arıkan-Ayyıldız Z, Karaman M, Tuncel T, Kiray M, Bağrıyanık A, Yilmaz O, Uzuner N, Karaman O. Beneficial effects of arginase inhibition and inhaled L-arginine administration on airway histology in a murine model of chronic asthma. Allergol Immunopathol (Madr). 2014 Jul-Aug;42(4):316-23. doi: 10.1016/j.aller.2013.01.001. Epub 2013 Apr 8. PubMed PMID: 23578782. 13: Tratsiakovich Y, Gonon AT, Krook A, Yang J, Shemyakin A, Sjöquist PO, Pernow J. Arginase inhibition reduces infarct size via nitric oxide, protein kinase C epsilon and mitochondrial ATP-dependent K+ channels. Eur J Pharmacol. 2013 Jul 15;712(1-3):16-21. doi: 10.1016/j.ejphar.2013.04.044. Epub 2013 May 9. PubMed PMID: 23665492. 14: Li X, Zhu F, He Y, Luo F. [Arginase inhibitor nor-NOHA induces apoptosis and inhibits invasion and migration of HepG2 cells]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017 Apr;33(4):477-482. Chinese. PubMed PMID: 28395717. 15: Ogino K, Kubo M, Takahashi H, Zhang R, Zou Y, Fujikura Y. Anti-inflammatory effect of arginase inhibitor and corticosteroid on airway allergic reactions in a Dermatophogoides farinae-induced NC/Nga mouse model. Inflammation. 2013 Feb;36(1):141-51. doi: 10.1007/s10753-012-9529-3. PubMed PMID: 22915279. 16: Gonon AT, Jung C, Katz A, Westerblad H, Shemyakin A, Sjöquist PO, Lundberg JO, Pernow J. Local arginase inhibition during early reperfusion mediates cardioprotection via increased nitric oxide production. PLoS One. 2012;7(7):e42038. doi: 10.1371/journal.pone.0042038. Epub 2012 Jul 31. PubMed PMID: 22860052; PubMed Central PMCID: PMC3409239. 17: Shemyakin A, Kövamees O, Rafnsson A, Böhm F, Svenarud P, Settergren M, Jung C, Pernow J. Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes mellitus. Circulation. 2012 Dec 18;126(25):2943-50. doi: 10.1161/CIRCULATIONAHA.112.140335. Epub 2012 Nov 26. PubMed PMID: 23183942. 18: Tenu JP, Lepoivre M, Moali C, Brollo M, Mansuy D, Boucher JL. Effects of the new arginase inhibitor N(omega)-hydroxy-nor-L-arginine on NO synthase activity in murine macrophages. Nitric Oxide. 1999 Dec;3(6):427-38. PubMed PMID: 10637120. 19: Bratt JM, Franzi LM, Linderholm AL, O'Roark EM, Kenyon NJ, Last JA. Arginase inhibition in airways from normal and nitric oxide synthase 2-knockout mice exposed to ovalbumin. Toxicol Appl Pharmacol. 2010 Jan 1;242(1):1-8. doi: 10.1016/j.taap.2009.09.018. Epub 2009 Oct 2. PubMed PMID: 19800904; PubMed Central PMCID: PMC3221650. 20: Huynh NN, Harris EE, Chin-Dusting JF, Andrews KL. The vascular effects of different arginase inhibitors in rat isolated aorta and mesenteric arteries. Br J Pharmacol. 2009 Jan;156(1):84-93. doi: 10.1111/j.1476-5381.2008.00036.x. PubMed PMID: 19133993; PubMed Central PMCID: PMC2697778.